Type 1 diabetes occurs in young people and is of rapid onset. Autoimmune destruction of the insulin-secreting b-cells of the pancreas is the major cause, marked by the presence of islet cell antibodies 1 and glutamic acid decarboxylase antibodies 2 in 70±80% of patients 3 . Type 2 diabetes mellitus, by contrast, is a disease of the middle aged or elderly and usually begins insidiously. Insulin resistance and a strong family history are the hallmarks. These are the typical pictures, but type 2 diabetes can develop in early adulthood and type 1 diabetes in the middle aged or elderly. In this paper I review the variants to be considered in a young adult (545 years) with diabetes mellitus of slowly progressive onset.
MATURITY ONSET DIABETES OF THE YOUNG (MODY)
MODY is early-onset type 2 diabetes, usually beginning under the age of 25 years. Those affected are seldom obese. The condition is inherited in autosomal dominant fashion and accounts for some 2±5% of type 2 diabetes 4 . GAD autoantibodies are not found. Five subtypes have so far been identi®ed, due to different gene defects 5 .
MODY due to HNF4a mutations on chromosome 20q (MODY 1) closely resembles classic type 2 diabetes. Several HNF4a mutations have been described (Q268X, F75fsdelT, K99fsdelAA, R127W, R154X, and E276Q) 6 . Under the age of 10 years most individuals who carry these mutations have a normal fasting blood glucose and normal glucose tolerance. Thereafter, glycaemic control deteriorates and diabetes is usually diagnosed between 12 and 35 years of age. The prevalence of microvascular and macrovascular complications is similar to that in classic type 2 diabetes. Impaired b-cell function seems to be the main reason for abnormal glucose control, insulin resistance being unimportant.
MODY due to mutations in the glucokinase (GCK) gene on chromosome 7 (MODY 2) is a milder form of diabetes. More than 45 GCK mutations have been described 7 . All patients have modest fasting hyperglycaemia from birth (6±8 mmol/L) and there is only slight deterioration over time 8 . Usually there are no symptoms and diagnosis is typically made on routine screening in a young person with a family history of type 2 diabetes mellitus in two or more generations. The main defect is in b-cell glucose sensing, caused by mutations in the glucokinase gene 9 ; thus, fasting glucose is set at a higher baseline. b-cell function is otherwise normal and the response to a glucose challenge is good. Patients with MODY 2 are highly sensitive to sulphonylurea medication and seldom get microvascular complications 10 .
MODY due to HNF1a mutations on chromosome 12q (MODY 3) is similar to MODY 1 in its clinical presentation 11 . More than 45 HNF-1a mutations have been described 12 .
MODY due to mutations in insulin promoter factor 1 (MODY 4) seems similar to MODY 1 and MODY 3 in phenotype but clinical details are limited. It arises when the mutated gene is present in the heterozygous state; homozygosity results in pancreatic agenesis 13 . The average age of onset is 35 years. Most patients require dietary management or oral hypoglycaemic agents 14 .
MODY 5, due to HNF1b mutations, is the most recently discovered subtype and presents between 12 and 28 years of age. Initial data suggest a clinical course similar to MODY 3 and MODY 4. Cystic renal disease and chronic renal failure appear to be associated with it 15 .
Subtypes of MODY are outlined in Table 1 .
EARLY ONSET TYPE 2 DIABETES (EOD)
With EOD the age of onset is between 25 and 40 years. Most patients are obese and commonly they are hypertensive and dyslipidaemic as well. Usually both parents are diabetic or have impaired glucose tolerance 16 , the mode of inheritance being autosomal dominant. Glutamic acid decarboxylase autoantibodies (GAD) are not usually found but about 10% of patients are positive for b-cell antibodies. At least in the early years, insulin is not needed. The insulin response to an oral glucose load is much more heterogeneous than in MODY3 diabetes 17 , and the primary defect seems to be a decrease in the response of peripheral tissues to insulin. A combination of early onset, hypertension, and dyslipidaemia puts these individuals at high risk of microvascular and macrovascular complications. Table 2 summarizes the differences between EOD and MODY.
LATENT AUTOIMMUNE DIABETES OF ADULTHOOD (LADA)
About 10% of patients diagnosed with diabetes have latent autoimmune diabetes of adulthood, characterized by the presence of glutaminic acid decarboxylase antibodies 18, 19 . This is a slowly progressive form of type 1 diabetes which usually presents after the age of 25 years. The clinical onset tends to be less acute than that of type 1 diabetes, and the initial diagnosis is commonly of type 2. The patients are younger and thinner than those with type 2, and they show some of the classic features of type 1 diabetes including weight loss, low C-peptide concentration, an increased frequency of HLA DR3 and DR4, and positive tests for islet cell and glutamic acid decarboxylase antibodies 20 . Although insulin secretion is better preserved in the slowly progressing than in the rapidly progressing form of autoimmune diabetes, patients are insulin de®cient and require insulin treatment early in their clinical course 21 . They also have some degree of insulin resistance 22 . There is an argument for checking for glutamic acid decarboxylase antibody in all newly diagnosed young and thin patients with type 2 diabetes since a positive result almost invariably means that the patient will require insulin 23 . Despite their lower body mass index, waist-to-hip ratio and C-peptide concentrations and higher HDL2 (high-density lipoprotein cholesterol) concentrations, LADA patients have about the same prevalence of microvascular and macrovascular complications as those with type 2 diabetes 24 .
MATERNALLY INHERITED DIABETES AND DEAFNESS (MIDD)
MIDD is type 2 diabetes caused by a mutation in mitochondrial DNA (3243 tRNA leu ) 25 with usual onset before the age of 40 years. The same mutation is associated with the syndrome of MELAS (mitochondrial myopathy, encephalopathy, lacticacidosis, and stroke-like episodes) 26 . Why some carriers develop MELAS and others diabetes is unclear. Recently another point mutation, characterized by a T?C transition at mtDNA position 14709 within the tRNAGlu gene, has been described 27 . A sensorineural hearing loss, not always leading to clinically manifest deafness, commonly precedes the onset of diabetes. Individuals with MIDD are usually not obese. Mitochondrial myopathy, from mild or even silent to severe, can be found in all patients if looked for 28 . Cardiac disorders, hypertension, nephropathy and spontaneous abortion have been frequently noted but whether these are true diabetic complications or comorbidities of the mutation is not known. About half of all diabetic patients who are`3243' carriers were previously diagnosed as having type 1 diabetes, though islet cell antibodies are either absent or very low 29 . MIDD patients tend to be insulinopenic, and the defect is thought to lie in insulin release rather than the producing capacity of b-cells 30 . The severity of glucose intolerance varies, manageable by diet and/or oral hypoglycaemic agents in some patients and requiring insulin in others; but ®ve years after diagnosis most patients will need insulin 31 . because the precise diagnosis has implications for prognoses, treatment and screening of family members.
